Recurrent erlotinib-induced interstitial lung disease on non-small cell lung cancer

Tuberculosis and Respiratory Diseases

Volumn 67, Issue 5, 2009, Pages 445-448

  Park, Sang Don ^a   Kim, Areum ^a   Park, Jin Seok ^a   Shin, Chun Ho ^a   Nam, Hae Sung ^a   Kim, Lucia ^a   Cho, Jae Wha ^a   Ryu, Jeong Sun ^a   Kwak, Seung Min ^a  

^a Inha University School of Medicine   (South Korea)

Author keywords

Carcinoma, non small cell lung; Erlotinib; Lung diseases, interstitial

Indexed keywords

CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; METHYLPREDNISOLONE; PEMETREXED;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG WITHDRAWAL; DYSPNEA; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; LABORATORY TEST; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MALE; PNEUMONIA; RADIOLOGY; RECURRENT DISEASE; THERAPY EFFECT; TREATMENT RESPONSE;

EID: 74049124346     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2009.67.5.445     Document Type: Article

References (12)

1. Johnson JR, Cohen M, Sridhara R, Chen Y, Williams GM, Duan J, et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005;11:6414-6421 (Pubitemid 41338977)
2. Spigel DR, Lin M, O'Neill V, Hainsworth JD. Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer. Cancer 2008;112:2749-2755 (Pubitemid 351969220)
3. Kato T, Nishio K. Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk. Respirology 2006;11:693-698 (Pubitemid 44581432)
4. Niho S, Kubota K, Goto K, Yoh K, Ohrnatsu H, Kakinuma R, et al. First-line single agent treatment with gefitinib in patients with advanced non- small-cell lung cancer: a phase II study. J Clin Oncol 2006;24:64-69 (Pubitemid 46630495)
5. Fukui T, Mitsudomi T. Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. Gen Thorac Cardiovasc Surg 2008;56:97-103.
6. Liu V, White DA, Zakowski MF, Travis W, Kris MG, Ginsberg MS, et al. Pulmonary toxicity associated with erlotinib. Chest 2007;132:1042-1044
7. Yoneda KY, Shelton DK, Beckett LA, Gandara DR. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. J Thorac Oncol 2007;2: 537-543
8. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003;8:303-306 (Pubitemid 36929716)
9. Makris D, Scherpereel A, Copin MC, Colin G, Brun L, Lafitte JJ, et al. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer 2007;7:150. (Pubitemid 47371517)
10. Kitajima H, Takahashi H, Harada K, Kanai A, Inomata S, Taniguchi H, et al. Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serum markers. Respirology 2006;11:217-220 (Pubitemid 43356904)
11. Suzuki M, Asahina H, Konishi J, Yamazaki K, Nishimura M. Recurrent gefitinib-induced interstitial lung disease. Intern Med 2008;47:533-536
12. Niho S, Goto K, Yoh K, Kim YH, Ohmatsu H, Kubota K, et al. Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs. Jpn J Clin Oncol 2006;36:269-273 (Pubitemid 43997330)